FindTrial
Sign In

Multicenter real-world study on the efficacy and safety of DS8201 in the treatment of metastatic breast cancer

Multicenter real-world study on the efficacy and safety of DS8201 in the treatment of metastatic breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400095081
Enrollment
Unknown
Registered
2024-12-31
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Observation group:None

Sponsors

The First Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old; 2. Pathological diagnosis of breast cancer; 3. Pathological or imaging evidence of the presence of one or more distant metastatic lesions; 4. Received DS8201 treatment; 5. Complete medical records, complete blood routine and liver and kidney function test results during the treatment period.

Exclusion criteria

Exclusion criteria: There is no history of traceability or lack of clinical data

Design outcomes

Primary

MeasureTime frame
Disease-free survival;Overall survival;—

Secondary

MeasureTime frame
Objective response rate;Disease control rate;Clinical benefit rate;—

Countries

China

Contacts

Public ContactZheng Lv

The First Hospital of Jilin University

lvz@jlu.edu.cn+86 158 0430 1705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026